Faricimab versus High-Dose Aflibercept for the Treatment of Neovascular AMD and DME


Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.

To watch the video series component of this episode, click here.

0:00 Introduction

1:05 Overview of faricimab and high-dose aflibercept

3:48 clinical trials for faricimab and high-dose aflibercept

9:12 Comparing the matched dose phase results in clinical trials

12:30 Potential impacts of Ang-2 inhibition

14:40 Real-world experience with faricimab

22:00 Challenges with step therapy

24:00 Choosing between faricimab vs high-dose aflibercept

29:00 Perspectives on retreatment criteria in clinical trials

33:00 Label differences between faricimab and high-dose aflibercept

35:00 Final remarks

Related Videos
Hong-Uyen Hua, MD; Sruthi Arepalli, MD; and Peter Kaiser, MD
Kelly Nichols, OD; Laura Periman, MD; and Mile Brujic, OD
Cindy X. Cai, MD: Impact of Race, Neighborhood on Diabetic Retinopathy Care | Image Credit: Johns Hopkins University
Dimitra Skondra, MD, PhD: Protective Effect of Metformin in Geographic Atrophy| Image Credit: University of Chicago
Deepak Sambhara, MD | Image Credit: American Society of Retina Specialists
Sean Adrean, MD: Impact of Baseline VA on Aflibercept 8 mg Outcomes in DME | Image Credit: Linkedin
Mark Barakat, MD: Stable IOP Outcomes After Aflibercept 8 mg in DME | Image Credit: Retina Macula Institute of Arizona
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
Dolly Chang, MD, PhD | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.